~~<i id='A188325241'><strike id='A188325241'><tt id='A188325241'><pre id='A188325241'></pre></tt></strike></i>~~

Home» leisure time» hotspot

hotspot

author：Wikipedia 2025-09-27 13:57:47 Page View：137

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： CDC recommends RSV monoclonal antibody for infants
Next article： At least 13 dead in Texas as scorching temps continue

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Medicare slashes safety net hospital payments by nearly $1 billion

Thefederalgovernmentwillpayhospitalsthattreatpooranduninsuredpatientsalmost$1billionlessnextyear.Ado

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

H.R. 3 is the wrong path to lower drug costs

Fromleft,Rep.RichardNeal(D-Mass.)speaksasRep.FrankPallone(D-N.J.)andHouseSpeakerNancyPelosi(D-Calif.

WSS

hotspot

hotspot

explore

knowledge

H.R. 3 is the wrong path to lower drug costs